The Pharmacy Times® Immunization Resource Center is a comprehensive resource for clinical news and expert insights on common immunizations, such as flu, zoster, and COVID-19 vaccines.
April 30th 2024
Notable contributions from female leaders in the pharmaceutical industry demonstrate the exceptional competence of women in vaccine innovation.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
FDA Approves First Respiratory Syncytial Virus Vaccine for Adults Aged 60 Years and Older
May 3rd 2023Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Read More
Pneumococcal Vaccine Candidate Shows Promise in Adults Aged 65 Years and Older
April 20th 2023VAX-24 is designed to prevent invasive pneumococcal disease and pneumonia, which can be most serious for infants, young children, older adults, and those with immune deficiencies or some chronic health conditions.
Read More
Johnson & Johnson Discontinues Phase 3 Study Evaluating Respiratory Syncytial Virus Vaccine
March 30th 2023The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.
Read More
Study: Linking Flu Vaccination, Potential Cardiovascular Benefits Increases Vaccination Rates
March 9th 2023Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.
Read More
Latest Developments in mRNA Technology for Vaccines: Moving Beyond COVID-19
March 2nd 2023Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.
Read More